# Treatment of hyperphenylalaninemia with Sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) and its influence on the amino acids and fatty acids patterns from childhood to adulthood (Tratamiento de la hiperfenilalaninemia con dihidrocloruro de Sapropterina [tetrahidrobiopterina, 6r-bh4] y su influencia en el patrón de aminoácidos y ácidos grasos desde la infancia hasta la edad adulta)

Submission date	Recruitment status	Prospectively registered
31/01/2011	No longer recruiting	[_] Protocol
Registration date	Overall study status	Statistical analysis plan
18/04/2011	Completed	[_] Results
Last Edited	Condition category	Individual participant data
18/04/2011	Nutritional, Metabolic, Endocrine	[] Record updated in last year

### Plain English summary of protocol

Not provided at time of registration

# **Contact information**

**Type(s)** Scientific

**Contact name** Dr Maria Concepción García Jiménez

#### **Contact details** Servicio de Pediatría. Unidad de Metabolismo. Hospital Universitario Miguel Servet. Paseo Isabel La Católica 1-3. Zaragoza Spain

50009 +34 607224828 igarciaji@salud.aragon.es

# Additional identifiers

EudraCT/CTIS number

**IRAS number** 

ClinicalTrials.gov number

Secondary identifying numbers EC81/00474

# Study information

#### Scientific Title

Treatment of hyperphenylalaninemia with Sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) and its influence on the amino acids and fatty acids patterns from childhood to adulthood, a Phase IV, longitudinal, unblinded, controlled, single-centre, retrospective and prospective clinical study

#### **Study objectives**

The aim of this study is to compare the response to dietary treatment or pharmacological treatment with Sapropterin in patients with hyperphenylalaninemia secondary to phenylalanine hydroxylase deficiency and to assess the blood profile of long-chain fatty acids and amino acids and its relationship with the metabolic control and other complications such as osteopenia.

Hyperphenylalaninemia (HPA) is a metabolic disorder mainly caused by a defect in the phenylalanine hydroxylase gene, which produces a deficiency of this enzyme resulting in an alteration of the metabolism of phenylalanine (Phe) and consequently its accumulation. Phe is toxic to the central nervous system, therefore an accumulation of Phe leads to an alteration in the psychomotor development. A strict diet can control the Phe blood level enough to avoid most of the serious neurological effects. However, dietary treatment presents some problems, such as difficult adherence, negative impact on the daily life of the patients or nutritional deficiencies. Sapropterin significantly reduces and maintains blood Phe concentrations with the subsequently improving quality of diet.

Sapropterin allows to partially or fully liberalize the diet with limited intake of phenylalanine in certain types of hyperphenylalaninemias. This will improve the quality of life of patients, as well as their neurological / cognitive development. Furthermore, in patients who have a good response to Sapropterin, this treatment is able to maintain certain biochemical parameters (total amino acids and essential fatty acids) equally or better controlled than the dietary treatment.

#### Ethics approval required

Old ethics approval format

Ethics approval(s)

Clinical Research Ethics Committee of Aragon [Comité Ético de Investigación Clínica de Aragón] Ref: C.I. EC09/055, 02/09/2009

#### Study design

Phase IV longitudinal retrospective and prospective unblinded controlled single-centre clinical studv

### Primary study design

Interventional

### Secondary study design

Randomised controlled trial

### Study setting(s)

Hospital

#### Study type(s) Treatment

#### Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

### Health condition(s) or problem(s) studied

Hyperphenylalaninemia (HPA)

#### Interventions

1. Male and female patients with hyperphenylalaninemia secondary to phenylalanine hydroxylase deficiency, controlled in the Metabolism Unit at Children's Hospital Miguel Servet, who respond to treatment with Sapropterin being able to leave the phenylalanine free diet completely or partially

2. The drug administered is Kuvan® (tablets of 100 mg) at a dose of 5-20 mg/kg/day orally (PO), in a single dose. Calculated dose will be rounded to the nearest 100 mg

3. Tablets should be dissolved in water (120 ml for children and 240 ml for adults), and solution should be drunk within 15-20 minutes after preparation

4. Control group: patients of both sexes, from birth, diagnosed with classic

hyperphenylalaninemia, controlled in the Metabolism Unit at Children's Hospital Miguel Servet, who have not responded to treatment with Sapropterin and are only under dietary treatment. 5. Every four months the following information will be collected:

5.1. Anthropometric variables (weight, height), phenylalanine tolerance by a nutrition survey which collects intakes for the previous three days. F

5.2. In subjects taking Sapropterin, daily dose, adherence to treatment, and adverse effects will also be collected

5.3. Biochemical parameters will be assessed every 4 months during the year following the beginning of the study, they will include: total amino acids, essential (AA) amino acids (phenylalanine, methionine, tryptophan, valine, leucine, isoleucine, histidine, lysine, tyrosine) and essential fatty acids

5.5. An estimation will be made of the ratios total AA/AA essential and Phe/Tyr before and after treatment with Sapropterin.

6. Total duration of treatment: 1 year

7. Total duration of follow-up: 28 days

### Intervention Type

Drug

**Phase** Phase IV

### Drug/device/biological/vaccine name(s)

1. Sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) 2. Kuvan®

#### Primary outcome measure

1. Every four months biochemical analysis of total amino acids and essential fatty acids as indicators of quality

2. Amino acids levels were analyzed by HPLC (cation-exchange high performance liquid chromatography)

3. The levels of essential fatty acids were determined by gas-liquid chromatography

#### Secondary outcome measures

1. Prevalence in our population of patients with hyperphenylalaninemia who respond to Sapropterin

2. Correlation between a type of mutation and the response to Sapropterin

3. Relationship in our population between the response to Sapropterin and the severity of biochemical phenotype and genotype

4. Profile of total and essential amino acids and fatty acids on patients treated with Sapropterin versus patients treated with diet. Liberalization of phenylalanine-free diet as much as possible 5. Diet liberalization will be assessed by increasing the amounts of Phe on the daily diet and controlling at the same time the Phe blood level is within the appropriate limits (less than 240 nmol/ml in children under 6 year-old, less than 360 nmol/ml in children of 6-10 year-old, and less than 500 nmol/ml in older than 10)

#### Overall study start date

12/03/2009

#### **Completion date**

25/11/2011

# Eligibility

#### Key inclusion criteria

1. Patients with hyperphenylalaninemia due to phenylalanine hydroxylase deficiency, who respond to treatment with Sapropterin

2. Childbearing women who should have a negative pregnancy test within 7 days prior to start of treatment with Sapropterin and should use reliable contraception during the whole study 3. The control group will include patients with hyperphenylalaninemia due to phenylalanine hydroxylase deficiency that are metabolically well controlled without Sapropterin

### Participant type(s)

Patient

**Age group** Other **Sex** Both

**Target number of participants** 30

**Key exclusion criteria** 1. Liver impairment or other underlying chronic disease that may require regular treatment 2. Pregnancy and breastfeeding

Date of first enrolment 12/03/2009

Date of final enrolment 25/11/2011

# Locations

**Countries of recruitment** Spain

**Study participating centre Servicio de Pediatría. Unidad de Metabolismo. Hospital Universitario Miguel Servet.** Zaragoza Spain 50009

### Sponsor information

**Organisation** Aragon Institute of Health Sciences [Instituto Aragonés de Ciencias de la Salud] (Spain)

#### Sponsor details

c/o Esteban de Manuel Keenoy Instituto Aragonés de Ciencias de la Salud Avenida Gómez Laguna, 25. Zaragoza Spain 50009 emlopezh.iacs@aragon.es

Sponsor type

Government

Website http://www.aragon.es/

ROR https://ror.org/05p0enq35

# Funder(s)

**Funder type** Government

**Funder Name** Aragon Institute of Health Sciences [Instituto Aragonés de Ciencias de la Salud] (Spain)

# **Results and Publications**

**Publication and dissemination plan** Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

**IPD sharing plan summary** Not provided at time of registration